Immunic, Inc.
Sağlık
NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.
$8.19
Price (1 Year)
Participation Finance Screening Ratios
Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.
About the Company
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Website ↗